Henry Schein, Inc. (NASDAQ:HSIC) – Analysts at Northcoast Research lowered their FY2017 earnings estimates for Henry Schein in a research report issued to clients and investors on Wednesday. Northcoast Research analyst E. Snyder now expects that the company will post earnings per share of $7.34 for the year, down from their prior forecast of $7.35. Northcoast Research has a “Buy” rating and a $218.00 price target on the stock. Northcoast Research also issued estimates for Henry Schein’s FY2018 earnings at $8.18 EPS.

Henry Schein (NASDAQ:HSIC) last posted its earnings results on Tuesday, August 8th. The company reported $1.75 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.73 by $0.02. Henry Schein had a net margin of 4.59% and a return on equity of 19.91%. The firm had revenue of $3.06 billion during the quarter, compared to analysts’ expectations of $3.05 billion. During the same period last year, the company posted $1.64 EPS. The company’s quarterly revenue was up 6.4% compared to the same quarter last year. TRADEMARK VIOLATION NOTICE: This news story was originally posted by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this news story can be accessed at https://www.watchlistnews.com/northcoast-research-analysts-reduce-earnings-estimates-for-henry-schein-inc-hsic/1537873.html.

HSIC has been the topic of a number of other research reports. Credit Suisse Group reaffirmed a “hold” rating and set a $175.00 price objective on shares of Henry Schein in a research note on Tuesday. BidaskClub lowered Henry Schein from a “hold” rating to a “sell” rating in a research note on Wednesday, August 2nd. Stifel Nicolaus increased their price objective on Henry Schein from $174.00 to $178.00 and gave the company a “hold” rating in a research note on Wednesday, May 10th. Zacks Investment Research upgraded Henry Schein from a “hold” rating to a “buy” rating and set a $204.00 target price on the stock in a research report on Thursday, May 25th. Finally, Piper Jaffray Companies started coverage on Henry Schein in a research report on Monday, June 12th. They set a “neutral” rating and a $200.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating and seven have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $186.50.

Shares of Henry Schein (HSIC) opened at 173.53 on Thursday. Henry Schein has a 52-week low of $146.23 and a 52-week high of $186.99. The stock has a 50 day moving average of $176.46 and a 200 day moving average of $176.07. The stock has a market capitalization of $13.72 billion, a PE ratio of 25.36 and a beta of 1.10. Henry Schein’s stock is scheduled to split on Friday, September 15th. The 2-1 split was announced on Wednesday, August 16th. The newly issued shares will be payable to shareholders after the market closes on Thursday, September 14th.

Institutional investors have recently added to or reduced their stakes in the company. Macquarie Group Ltd. increased its position in Henry Schein by 84.0% in the fourth quarter. Macquarie Group Ltd. now owns 4,600 shares of the company’s stock worth $698,000 after buying an additional 2,100 shares during the period. Candriam Luxembourg S.C.A. purchased a new position in Henry Schein during the first quarter worth approximately $207,000. Waldron LP purchased a new position in Henry Schein during the first quarter worth approximately $286,000. Korea Investment CORP increased its position in Henry Schein by 38.7% in the first quarter. Korea Investment CORP now owns 23,714 shares of the company’s stock worth $4,031,000 after buying an additional 6,617 shares during the period. Finally, Profund Advisors LLC increased its position in Henry Schein by 3.4% in the first quarter. Profund Advisors LLC now owns 7,173 shares of the company’s stock worth $1,219,000 after buying an additional 239 shares during the period. Institutional investors own 89.08% of the company’s stock.

About Henry Schein

Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.

Earnings History and Estimates for Henry Schein (NASDAQ:HSIC)

Receive News & Ratings for Henry Schein Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.